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Despite these encouraging results, attempts to replace
all 3 pulmonary valve leaflets were unsatisfactory
because of the relatively high initial rigidity of the
PGA-PLA scaffold tissue-engineered leaflets.
In this study we tested a new biodegradable, biore-
sorbable, and thermoplastic polymer, polyhydroxyoc-
tanoate (PHO), seeded with autologous vascular cells in an
I n recently published studies our laboratory has beenable to replace successfully a single pulmonary valve
leaflet1 or segments of the main pulmonary artery2 by
using tissue-engineering principles (Fig 1). These
experiments have been conducted by using a biodegrad-
able scaffold of polyglycolic acid (PGA) and polylactic
acid (PLA) seeded with autologous vascular cells.
Objective: Bioprosthetic and mechanical valves and valved conduits are
unable to grow, repair, or remodel. In an attempt to overcome these short-
comings, we have evaluated the feasibility of creating 3-leaflet, valved, pul-
monary conduits from autologous ovine vascular cells and biodegradable
polymers with tissue-engineering techniques.
Methods: Endothelial cells and vascular medial cells were harvested from
ovine carotid arteries. Composite scaffolds of polyglycolic acid and polyhy-
droxyoctanoates were formed into a conduit, and 3 leaflets (polyhydroxyoc-
tanoates) were sewn into the conduit. These constructs were seeded with
autologous medial cells on 4 consecutive days and coated once with autolo-
gous endothelial cells. Thirty-one days (±3 days) after cell harvesting, 8
seeded and 1 unseeded control constructs were implanted to replace the pul-
monary valve and main pulmonary artery on cardiopulmonary bypass. No
postoperative anticoagulation was given. Valve function was assessed by
means of echocardiography. The constructs were explanted after 1, 2, 4, 6, 8,
12, 16, and 24 weeks and evaluated macroscopically, histologically, and bio-
chemically.
Results: Postoperative echocardiography of the seeded constructs demon-
strated no thrombus formation with mild, nonprogressive, valvular regurgi-
tation up to 24 weeks after implantation. Histologic examination showed
organized and viable tissue without thrombus. Biochemical assays revealed
increasing cellular and extracellular matrix contents. The unseeded construct
developed thrombus formation on all 3 leaflets after 4 weeks.
Conclusion: This experimental study showed that valved conduits construct-
ed from autologous cells and biodegradable matrix can function in the pul-
monary circulation. The progressive cellular and extracellular matrix forma-
tion indicates that the remodeling of the tissue-engineered structure
continues for at least 6 months. (J Thorac Cardiovasc Surg 2000;119:732-40)
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initial feasibility study for the creation of a 3-leaflet heart
valve in the supravalvular pulmonary valve position.
Materials and methods
The general approach to cell isolation, culture, sorting, and
seeding was described in detail previously.3 Several modifi-
cations have been made in these experiments.
Cell isolation and culture. Segments of the common
carotid artery (2-3 cm) were harvested from 6-week-old
Dover lambs (n = 8). Endothelial cells were obtained by using
a collagenase instillation technique for 20 minutes at 37°C at
95% oxygen and 5% carbon dioxide (0.2% collagenase type
A [Boehringer Mannheim] in 1% bovine serum albumin
[Sigma]) and cultured in gelatin precoated (1% gelatin
[Sigma]) tissue culture flasks (Corning Inc) by using Medium
199 (Gibco) supplemented with 10% fetal bovine serum
(Sigma), 1% L-glutamine, penicillin, streptomycin (Sigma),
and 50 IU/mL heparin (Promega). The media was changed
either every 3 days or during passaging.
The remaining de-endothelialized vessel segments were
minced into 1-mm2 pieces and cultured in Dulbecco’s modi-
fied Eagle’s medium high glucose (Gibco) supplemented
with 10% fetal bovine serum, 1% L-glutamine, penicillin, and
streptomycin on P100 dishes (Corning). After migration of
medial cells onto the dishes (7-10 days after the harvest), the
cells were serially passaged on 1% collagen-precoated tissue-
culture ware (Corning). Approximately 14 additional days
were needed to obtain 12 confluent T75 tissue-culture flasks
(Corning).
Biodegradable polymer and conduit design. The PHO
was provided from Metabolix Inc, the PGA was purchased
from Smith and Nephew Inc, and polydioxanone was pur-
chased from Ethicon, Inc.
The conduit (20 mm in length and 18 mm in internal diam-
eter) was composed of nonporous PHO film (240-µm thick)
with layers of PGA felt (1-mm thickness) on the inside and
outside of the PHO. The leaflets consisted of a monolayer of
porous PHO (120-µm thickness). A salt-leaching technique4
was used to create a porous material (pore sizes of 80-180
µm; Fig 2, A) for the leaflets. The leaflets were sutured to the
conduit wall by using 6-0 polydioxanone running sutures
(Fig 2, B). After completion of the suturing, the conduits were
immersed for 24 hours in 2% polyvinyl alcohol (Sigma) to
decrease hydrophobic surface characteristics and increase the
wettability of the PHO. After air drying, the constructs were
sterilized with cold ethylene oxide.
Cell seeding. After 23 days (±3 days) in cell culture, an
average of 17.38 × 106 (±0.9 × 106) medial cells were dripped
onto the construct on each of 4 consecutive days. Finally,
14.85 × 106 (±0.25 × 106) endothelial cells were seeded once
on the inside of the construct. The polymer constructs were
precoated before the seeding with laminin (5 µg/mL [Sigma])
for 24 hours to improve cell-polymer attachment. The con-
structs were cultured in Dulbecco’s modified Eagle’s medium
high glucose supplemented with 10% fetal bovine serum, 1%
L-glutamine, penicillin, and streptomycin in tissue-culture
plastic ware.
After 1 final incubation day in an Erlenmeyer flask
(Corning) with culture media, the constructs were implanted.
Implantation. At 31 days (±3 days) after the initial cell
harvest, the same 8 animals from which the initial vessel was
harvested (average weight, 25 ± 5 kg) underwent replace-
Fig 1. Concept of tissue engineering. Initial vessel harvest (step I) is followed by cell isolation and culture and
seeding of the scaffold with further in vitro culturing. The seeded scaffold is implanted back into the same animal
(step II).
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ment of the pulmonary valve and main pulmonary artery
with an autologous tissue-engineered valved conduit. In one
other animal an acellular polymer valved conduit was
implanted. Anesthesia was induced with 2 mg/kg ketamine,
0.02 mg/kg atropine, and an intravenous bolus infusion of 2
mg/kg propofol. Anesthesia was maintained by use of
inhalational isofluorane. The heart was exposed by a left
anterolateral thoracotomy entering the chest through the 4th
intercostal space. Systemic anticoagulation was induced
with 400 IU of heparin per kilogram. By means of femoral
arterial and right atrial venous cannulation, normothermic
cardiopulmonary bypass was established. On bypass, 0.01
mg/kg fentanyl and 0.02 mg/kg pancuronium were adminis-
tered to ensure anesthesia. With the heart beating, the pul-
monary artery was transected, and a segment of the main
pulmonary artery and all 3 native leaflets were removed. The
valved conduit was implanted by using running 5-0 monofil-
ament sutures (Prolene, Ethicon, Inc). Heparin was reversed
with 300 IU of protamine per kilogram after weaning from
bypass. The thoracic wall was closed in layers by using
resorbable sutures, and an intercostal nerve block with
0.25% bupivacaine was administered. No further anticoagu-
lation was given. All animals received 1000 mg of cefazolin
(Apothecon) for the first postoperative week on a daily basis.
For pain control, intramuscular buprenorphin injections were
given for the first 3 days and thereafter as necessary. All ani-
mals received humane care in compliance with the “Guide
for the Care and Use of Laboratory Animals” published by
the National Institutes of Health (National Institutes of
Health publication No. 85-23, revised 1985). After 7 days in
Children’s Hospital research facilities, the animals were
moved to an off-site indoor housing facility.
Evaluation of the tissue-engineered tricuspid conduits.
After implantation, Doppler echocardiography with either an
Accuson 128 or Hewlett-Packard Sonos 1500 Cardiac Imager
equipped with a 7- to 7.5-MHz phased-arrayed transducer
was used periodically to evaluate valve function. Two-dimen-
sional echocardiographic cDoppler examination was per-
formed of the right ventricular outflow tract, conduit, and dis-
tal main pulmonary artery immediately before chest closure.
Subsequent evaluations after 1, 2, 4, 6, 8, 12, and 24 weeks
included imaging of the conduit and leaflets from a long- and
short-axis view. Qualitative evaluation of pulmonary valve
competence was made by using color flow Doppler mapping.
The explanted conduit wall and the leaflets were evaluated
macroscopically and histologically. For determination of cel-
lular and extracellular components of the conduit wall, histo-
chemical assays were performed. DNA content was mea-
sured by using a commercially available cell proliferation
assay kit (CyQuant, Molecular Probes Inc). For determina-
tion of collagen content, tissue 4-hydroxyproline levels were
determined.5 Elastin was quantified after tissue extraction by
using 0.1% hot oxalic acid with a FASTIN elastin assay
(Biocolor Ltd) and proteoglycan-glycosaminoglycan content
after tissue extraction with guanidine HCl with a BLYSCAN
proteoglycan-glycosaminoglycan assay (Biocolor Ltd).
Molecular weight of the PHO material after explantation was
determined by using gel-permeation chromatography. Isolated
polymers were dissolved in chloroform at approximately 1
mg/mL, and samples (50 µL) were evaluated by chromatogra-
phy on a Waters Stryagel HT6E column at a flow rate of 1 mL
of chloroform per minute at room temperature by using a
refractive index detector. Molecular masses were determined
relative to polystyrene standards of narrow polydispersity.
Results
All animals survived the operative procedure.
Doppler echocardiography revealed no signs of throm-
bus formation on the conduit wall or on the leaflets of
A B
Fig 2. A, Polymer scaffold (frontal view) 18 mm in diameter and 20 mm in length. A 240-µm nonporous PHO
conduit wall with 1-mm nonwoven PGA felts on the inside and outside was used. Three leaflets of porous PHO
were sutured into the conduit. B, Sketch of scaffold design.
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the cellular conduits (Fig 3, A and B). In two animals the
echocardiography results suggested one nonfunctioning
leaflet with questionable attachment to the conduit wall.
Increasing scar tissue formation and the overlying lung
around the tissue-engineered conduit eventually limited
the echocardiographic window in all cases.
The macroscopic evaluation of the seeded conduits
showed no signs of thrombus formation with clear evi-
dence of tissue formation and a shiny surface of the
leaflets and the conduit wall. In each of the two animals
with suspicious echocardiographic results, one leaflet
was found to be fused to the conduit wall. At 24 weeks
after implantation, the conduit showed a marked thick-
ening of the conduit wall (Fig 4, A and B). In none of
the conduits was an increase in diameter observed. The
unseeded control construct showed after 4 weeks of in
vivo severe thrombus formation on all 3 leaflets (Fig 4, C).
The histologic examination of the conduit wall
showed laminated fibrous tissue uniformly covering the
surface. Transmural cords of vascularized tissue–filled
interstices were created by partial degradation of the
polymer. Flattened cells, resembling endothelial cells,
covered the luminal surface of the conduit wall and
extended onto the proximal leaflets. Immunohisto-
chemical staining with human von Willebrand factor
confirmed this observation. Healing was less complete
on the leaflets than on the conduit wall. A Movat pen-
tachrome stain, which stains elastin black, collagen
yellow, and glycosaminoglycans blue-green, showed
significant amounts of stainable collagen and proteo-
glycans but no stainable elastin. There was essentially
no thrombus formation and a mild foreign body
response to the polymer (Fig 5, A-C).
The biochemical assays revealed the following results.
The DNA content of the conduit wall progressively
increased to reach 62% of the native pulmonary artery
after 6 months, indicating gradually increasing cellulari-
ty (Fig 6, A). The 4-hydroxyproline content as a measure
of collagen content increased over the observed time and
reached a maximum of 460% of the native pulmonary
artery after 6 months (Fig 6, B). The elastin assay
revealed a steady increase with a maximum content of
215% of the native pulmonary artery after 16 weeks (Fig
6, C). The determination of proteoglycans and gly-
cosaminoglycans in the explanted conduits showed a
continuing production of these extracellular matrix com-
ponents with a maximum content exceeding the native
pulmonary artery by 180% (Fig 6, D).
Although histologic examination after 6 weeks did
not show any significant PGA, PHO material was still
evident in the conduit and the leaflets at 24 weeks.
Analysis of the residual PHO indicated a molecular
weight loss of 26%, suggesting a much longer degra-
dation profile for PHO than PGA (Fig 7).
Discussion
Prosthetic heart valves are durable and have good
flow dynamics, but they have well-known limita-
tions, including thrombogenicity, susceptibility to
infection, and lack of growth potential. Homograft
valves are less thrombogenic and may be more resis-
tant to infection but lack growth potential and are less
durable than prosthetic valves.6 In the pediatric pop-
ulation the incidence of calcification of homografts is
high as well.7 None of the currently used heart valve
devices meet the criteria for an ideal valve replace-
ment outlined by Harken and Curtis8 many years ago
(Table I).
These limitations of currently available prosthetic
and bioprosthetic valves and conduit arteries have led
us to investigate the tissue-engineering approach to
constructing valves and arteries.
Tissue engineering is an interdisciplinary field that
applies the principles of engineering and the life sci-
A B
Fig 3. Echocardiographic assessment. A, Sixteen weeks after implantation: long axis. B, Sixteen weeks after
implantation: short axis. One leaflet was fused with the conduit wall.
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ences toward the development of biologic substitutes
that restore, maintain, or improve tissue function.9 The
principal concept is the use of a scaffold material pre-
formed in the shape of the desired organ or structure on
which to deliver viable cellular tissue components.
Theoretically, the scaffold will provide a temporary
biomechanical profile for the replacement tissue until
the cells produce their own extracellular matrix. The
structural integrity and biomechanical profile for the
newly developed tissue structure ultimately depends on
this matrix formation. During this process of tissue for-
mation, the scaffold would gradually degrade and
resorb and be replaced by the new tissue, eventually
leaving no foreign scaffold material within the replaced
tissue (Fig 1).10,11
In previous experiments we used a combination of
PGA and PLA as the scaffold material for the cre-
ation of single pulmonary valve leaflets and pul-
monary artery segments.1,2 Despite the rapid degra-
dation time (approximately 6 weeks), this polymer
has several drawbacks. The tissue constructs formed
on PGA, with or without PLA, was stiff and conse-
quently less desirable for the creation of a 3-leaflet
heart valve.
As an alternative polymer scaffold for tissue engi-
neering, this study evaluated PHO. These are naturally
occurring thermoplastic polymers, which are biocom-
patible, resorbable, and extremely flexible and induce
only a minimal inflammatory response.12 In recent
experiments of our laboratory, infrarenal aortic seg-
ments were replaced by using a seeded copolymer of
PGA and nonporous PHO.13 The favorable results of
this study led us to use the same concept for the cre-
ation of a 3-leaflet conduit. Experiments with the use of
the same copolymer concept on leaflets (PGA-PHO-
PGA copolymer) failed because of thrombus formation
and lack of good tissue formation on the tissue-engi-
neered leaflets. In an attempt to capitalize on the flexi-
bility and strength of PHO while increasing cell attach-
ment and ingrowth, we used salt leaching to create a





Fig 4. A, Gross appearance of tissue-engineered seeded conduit 24 weeks in vivo (proximal view). B, Gross
appearance of tissue-engineered seeded conduit 24 weeks in vivo (distal view). Clear separation of all 3 leaflets




Fig 5. A, Proximal leaflet (16 weeks in vivo) with stain highlighting extracellular matrix elements showing pres-
ence of collagen (yellow) and proteoglycans (green). Central space in each photograph represents polymer dis-
solved during histology. B, Proximal leaflet (16 weeks in vivo) showing fibrous encapsulation ingrowth and
absence of thrombus. C, Conduit wall (16 weeks in vivo), with fibrous encapsulation and ingrowth of tissue
replacing parts of the polymer. (A, Movat pentachrome stain, magnification ×40; B and C, hematoxylin and eosin
stain, magnification ×100.)
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The histologic examination of this study revealed a
uniform, organized, fibrous tissue incorporating the con-
duit wall with an internal endothelial cell lining. Staining
showed large amounts of extracellular matrix, including
collagen and proteoglycans, in the conduit wall. The bio-
chemical assay for extracellular matrix detected concen-
trations of collagen, proteoglycans-glycosaminoglycans,
and elastin, which exceeded the native pulmonary artery
significantly. The leaflets showed a similar histologic
pattern with less tissue maturity than the conduit wall but
an organized fibrous tissue pattern, with flattened cells
corresponding to endothelial cells proximally. In addi-
tion, abundant collagen and proteoglycans were present.
The explanation for the discrepancy between the elastin
assay and the absence of stainable elastin on histologic
study is not clear, but it may be due to greater dispersion
of elastin in the tissue-engineered conduit than in the
native artery.
There was no increase in diameter or length of our
constructs over the observed time period. This lack of
growth is most likely related to the long degradation
time of the PHO. Although no PGA could be detected
histologically after 8 weeks in vivo, the PHO used for
the conduit wall and the leaflets persisted. The degra-
dation of both polymers, PHO and PGA, is known to
occur by hydrolysis.12 Although this hydrolysis is
known to take 6 to 8 weeks for PGA, we now know
from recent publications that the degradation and
resorption of plain PHO film exceeds 52 weeks.12 The
hydrolysis is theoretically determined by surface area.
Unpublished results from our laboratory, however,
have shown that although salt leaching increases the
surface area of PHO, the rate of degradation of PHO is
not altered (Stock and associates, unpublished results).
On the basis of these findings, we believe that the ideal
polymer for the creation of a 3-leaflet conduit should
A B
C D
Fig 6. A, DNA content of conduit in percentage of native pulmonary artery. B, 4-Hydroxyproline content of con-
duit in percentage of native pulmonary artery. C, Elastin content of conduit in percentage of native pulmonary
artery. D, Proteoglycan-glycosaminoglycan content of conduit in percentage of native pulmonary artery.
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degrade and resorb faster than the PHO used in these
studies.
Active research to alter the surface of PHO by using
different manufacturing techniques to improve the
degradation time and evaluation of other polyhydroxy-
alkanoates (Metabolix Inc) are currently underway at
this institution, and we are currently attempting to
improve the scaffold design by use of techniques such
as 3-dimensional printing and injection molding tech-
niques.14
In addition to polymer- and scaffold design–related
limitations, several cell biology issues remain to be clar-
ified. In this and prior experiments we used vascular
cells derived from carotid artery explants. It is unlikely
that this concept will be applicable to clinical situations,
and therefore we are currently investigating the feasibil-
ity of using the peripheral vein as the source of donor
cells. Mesenchymal stem cells and circulating bone
marrow–derived endothelial cells15,16 may represent an
additional source of cells. A critical issue in tissue engi-
neering is whether the cell populations in and on the
constructs are derived from the cells that were seeded on
the leaflets and conduit wall or originate from the prox-
imal and distal native pulmonary artery or from circu-
lating pluripotent stem cells. However, reliable cell-
labeling techniques for long-term implantations were
not available when these studies were undertaken. A
recent publication by Fox and colleagues17 evaluated for
the first time optimal labeling conditions for endothelial
cells, yielding greatest fluorescence over time without
adversely affecting cell viability. Finally, the production
and degradation of extracellular components is an
important process in the development and modeling of
tissue-engineered structures. In this study biochemical
assays revealed significantly increased values for colla-
gen, elastin, and proteoglycan-glycosaminoglycans
contents, indicating either an increased matrix deposi-
tion, a decreased matrix degradation, or both. Normal
matrix protein turnover is mediated by a family of
enzymes, the matrix metalloproteinases (MMPs), and
their natural inhibitors, the tissue inhibitors of metallo-
proteinases (TIMPs). The balance of MMP and TIMP
activity modulates extracellular matrix remodeling.18,19
We are currently investigating the activity of MMPs and
TIMPs in our tissue-engineered constructs to achieve a
better understanding of the complex process of tissue
formation and remodeling.
Conclusion
In this study we have fabricated a 3-leaflet heart
valve that is able to function for up to 6 months in the
pulmonary artery circulation by using tissue-engi-
neering techniques. The porous PHO in the leaflets
appeared more favorable to appropriate tissue forma-
tion than the film in the conduit wall. However, fur-
ther work is needed to optimize the scaffold configu-
ration, polymer resorption rate, cell harvesting, and
culture conditions to promote the formation of tissue
with the appropriate amounts and distribution of
matrix proteins. Further advances in polymer sci-
ences, manufacturing techniques, and cell biology
offer the potential for improvement, and we are opti-
mistic that the creation of tissue-engineered heart
valves will become possible in the long run.
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Discussion
Dr Alain F. Carpentier (Paris, France). I congratulate the
authors on a very interesting study. I published an experi-
mental study similar to yours, entitled “Collagen-Derived
Heart Valves,” in The Journal of Thoracic and Cardio-
vascular Surgery in 1971 (1971;62:707-13). I wish to share
with you what we have learned from this study in the hope
that it may be helpful to you.
First, if you make a valved conduit without Valsalva sinus-
es, a fibrous retraction of the cusps takes place after a few
months, whatever the type of tissue-engineered valve. With
a longer follow-up, you may be confronted with this compli-
cation. If you see it, rather than blaming the valve, I suggest
that you make a new conduit with Valsalva sinuses, which
will give your tissue-engineered valve the best chance of
success.
With regard to the cultivated cells you used, it was not clear
whether you used fibroblasts, smooth cells, or endothelial
cells. Also, what was the proportion of these different cells
and their position in the valve tissue?
Dr Stock. We undertook these experiments as an initial
feasibility study to test the concept of tissue engineering of a
3-leaflet heart valve. We are well aware that a normal semi-
lunar valve has the sinuses of Valsalva, and in this case we do
not have any sinuses. We are now working with different
manufacturers with 3-dimensional printing and injection
molding techniques, to make a semilunar valve that really is
like an identical copy of a human or an animal heart valve; we
then include the sinus. 
Dr Carpentier. Very simply, are these cells endothelial
cells or are they fibroblast cells? 
Dr Stock. We have endothelial cells, and we have mixed
cells of smooth muscle cells and fibroblasts. We have two
populations. 
Dr Carpentier. If you have a mixed population, I am sure
you are aware that the fibroblasts may develop at the expense
of the endothelial cells. Would it not be better to have only
endothelial cells?
Dr Stock. We cultured them separately, and therefore we
have one dish with endothelial cells and one dish with smooth
muscle cells and fibroblasts. This is a complete separation.
Dr Carpentier. Thank you. I do hope that with the more
accurate techniques and materials that we have today, you are
going to overcome the problem of tissue retraction that we
encountered in the past.
